Your browser doesn't support javascript.
loading
Preclinical Characterization of the Tau PET Tracer [18F]SNFT-1: Comparison of Tau PET Tracers.
Harada, Ryuichi; Lerdsirisuk, Pradith; Shimizu, Yuki; Yokoyama, Yuka; Du, Yiqing; Kudo, Kaede; Ezura, Michinori; Ishikawa, Yoichi; Iwata, Ren; Shidahara, Miho; Ishiki, Aiko; Kikuchi, Akio; Hatano, Yuya; Ishihara, Tomohiko; Onodera, Osamu; Iwasaki, Yasushi; Yoshida, Mari; Taki, Yasuyuki; Arai, Hiroyuki; Kudo, Yukitsuka; Yanai, Kazuhiko; Furumoto, Shozo; Okamura, Nobuyuki.
Affiliation
  • Harada R; Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan; ryuichi.harada.c8@tohoku.ac.jp.
  • Lerdsirisuk P; Division of Brain Science, Department of Aging Research and Geriatric Medicine, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan.
  • Shimizu Y; Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan.
  • Yokoyama Y; Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan.
  • Du Y; Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan.
  • Kudo K; Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Ezura M; Division of Brain Science, Department of Aging Research and Geriatric Medicine, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan.
  • Ishikawa Y; Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Iwata R; Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan.
  • Shidahara M; Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan.
  • Ishiki A; Department of Quantum Science and Energy Engineering, Tohoku University, Sendai, Japan.
  • Kikuchi A; Division of Brain Science, Department of Aging Research and Geriatric Medicine, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan.
  • Hatano Y; Division of Community Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
  • Ishihara T; Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Onodera O; Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.
  • Iwasaki Y; Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.
  • Yoshida M; Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.
  • Taki Y; Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan; and.
  • Arai H; Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan; and.
  • Kudo Y; Division of Brain Science, Department of Aging Research and Geriatric Medicine, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan.
  • Yanai K; Division of Brain Science, Department of Aging Research and Geriatric Medicine, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan.
  • Furumoto S; Division of Brain Science, Department of Aging Research and Geriatric Medicine, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan.
  • Okamura N; Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan.
J Nucl Med ; 64(9): 1495-1501, 2023 09.
Article in En | MEDLINE | ID: mdl-37321821
Tau PET tracers are expected to be sufficiently sensitive to track the progression of age-related tau pathology in the medial temporal cortex. The tau PET tracer N-(4-[18F]fluoro-5-methylpyridin-2-yl)-7-aminoimidazo[1,2-a]pyridine ([18F]SNFT-1) has been successfully developed by optimizing imidazo[1,2-a]pyridine derivatives. We characterized the binding properties of [18F]SNFT-1 using a head-to-head comparison with other reported 18F-labeled tau tracers. Methods: The binding affinity of SNFT-1 to tau, amyloid, and monoamine oxidase A and B was compared with that of the second-generation tau tracers MK-6240, PM-PBB3, PI-2620, RO6958948, JNJ-64326067, and flortaucipir. In vitro binding properties of 18F-labeled tau tracers were evaluated through the autoradiography of frozen human brain tissues from patients with diverse neurodegenerative disease spectra. Pharmacokinetics, metabolism, and radiation dosimetry were assessed in normal mice after intravenous administration of [18F]SNFT-1. Results: In vitro binding assays demonstrated that [18F]SNFT-1 possesses high selectivity and high affinity for tau aggregates in Alzheimer disease (AD) brains. Autoradiographic analysis of tau deposits in medial temporal brain sections from patients with AD showed a higher signal-to-background ratio for [18F]SNFT-1 than for the other tau PET tracers and no significant binding with non-AD tau, α-synuclein, transactiviation response DNA-binding protein-43, and transmembrane protein 106B aggregates in human brain sections. Furthermore, [18F]SNFT-1 did not bind significantly to various receptors, ion channels, or transporters. [18F]SNFT-1 showed a high initial brain uptake and rapid washout from the brains of normal mice without radiolabeled metabolites. Conclusion: These preclinical data suggest that [18F]SNFT-1 is a promising and selective tau radiotracer candidate that allows the quantitative monitoring of age-related accumulation of tau aggregates in the human brain.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neurodegenerative Diseases / Alzheimer Disease Limits: Animals / Humans Language: En Journal: J Nucl Med Year: 2023 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neurodegenerative Diseases / Alzheimer Disease Limits: Animals / Humans Language: En Journal: J Nucl Med Year: 2023 Document type: Article Country of publication: